14th Jun 2018 12:02
LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating polyneuropathy.
Shares were trading 6.9% higher at 24.70 pence each following the news.
CIDP is a autoimmune-mediated inflammatory disease of the peripheral nervous system. Currently there are no specific treatment for it.
The drug development company said that the mechanism of action of P140 can "potentially be applied to a number of other auto-immune diseases in addition to Lupus".
The compound also displayed prophylactic and therapeutic effects, both in terms of disease intensity and chronicity, the company said.
Related Shares:
Immupharma